Chadi welcomes “Papa Heme,” or Aaron Goodman, MD, hematologist at University of California San Diego, and Matt Wilson, MD, Beatson West of Scotland Cancer Centre (UK), to debate the importance and utility of CNS prophylaxis for patients with DLBCL. The trio explain the origins of the debate, who the high-risk patients are in the first place, whether better systemic control is a better strategy for these patients, how to weigh the benefits against the toxicities and other negative effects, and so much more. You don’t want to miss this informative and at times contentious dialogue.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
